Search
for
Sort by
Research 901–930 of 1000+
- Use of Finasteride and Spironolactone in Hospitalized COVID-19 Patients and Their Effect on Severity Outcomes
- Occurrence and persistence of symptoms, diagnoses and prescriptions after community-diagnosed COVID-19: a matched cohort study using the OpenSAFELY platform
- Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19
- Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature
- Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
- Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomes
- The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression Levels in Patients with Comorbidities on COVID-19 Severity: A Comprehensive Review
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
- 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
- Clinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: a retrospective cohort analysis
- Changes in dermatological complaints among healthcare professionals during the COVID-19 outbreak in Turkey
- Roles of existing drug and drug targets for COVID-19 management
- A Review of the Dermatological Manifestations of Coronavirus Disease 2019 (COVID-19)
- Expression of concern: potential risk for developing severe COVID-19 disease among anabolic steroid users
- Change of the diagnostic distribution in applicants to dermatology after COVID ‐19 pandemic: What it whispers to us?
- The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis
- Do Anti-androgens Have Potential as Therapeutics for COVID-19?
- Induced pluripotent stem cells: Generation methods and a new perspective in COVID-19 research
- Weathering the Storm: Harnessing the Resolution of Inflammation to Limit COVID-19 Pathogenesis
- Opportunistic pathogenic fungal co-infections are prevalent in critically ill COVID-19 patients: Are they risk factors for disease severity?
- Patients with bullous skin disease in a high‐epidemic COVID‐19 area, Bergamo, Italy
- Comparison of patients’ diagnoses in a dermatology outpatient clinic during the COVID‐19 pandemic period and pre‐pandemic period
- Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center
- Solanum nigrum L. in COVID-19 and post-COVID complications: a propitious candidate
- A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome
- The impact of certain genetic variants (single nucleotide polymorphisms) on incidence and severity of COVID‐19
- Shedding light on therapeutics in alopecia and their relevance to COVID-19
- Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
- Efficacy of QR678 Neo<sup>®</sup> hair growth factor formulation for the treatment of hair loss in Covid‐19‐induced persistent Telogen Effluvium—A prospective, clinical, single‐blind study
- Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial